A model of GLP-1 action on insulin secretion in nondiabetic subjects

American Journal of Physiology - Endocrinology and Metabolism

Volumn 298, Issue 6, 2010, Pages

  Dalla Man, Chiara ^a   Micheletto, Francesco ^a   Sathananthan, Airani ^b   Rizza, Robert A ^b   Vella, Adrian ^b   Cobelli, Claudio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Mayo Clinic   (United States)

Author keywords

cell responsivity; C peptide; Glucagon like peptide 1; Hyperglycemic clamp; Incretins; Parameter estimation

Indexed keywords

C PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN;

ADULT; ARTICLE; BODY MASS; DRUG MECHANISM; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLYCEMIC CONTROL; HUMAN; HUMAN EXPERIMENT; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; STATISTICAL MODEL;

ADULT; BLOOD GLUCOSE; C-PEPTIDE; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE CLAMP TECHNIQUE; HUMANS; INFUSIONS, INTRAVENOUS; INSULIN; INSULIN-SECRETING CELLS; MALE; MODELS, BIOLOGICAL;

EID: 77952588236     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00705.2009     Document Type: Article

References (33)

1. Ahrén B, Holst JJ, Mari A. Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans. Diabetes Care 26: 2860-2864, 2003. (Pubitemid 37205559)
2. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP (Review). Gastroenterology 132: 2131-2157, 2007.
3. Barrett PH, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, Foster D. SAAM II: Simulation, Analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism 47: 484-492, 1998.
4. Breda E, Cavaghan MK, Toffolo G, Polonsky KS, Cobelli C. Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity. Diabetes 50: 150-158, 2001.
5. Campioni M, Toffolo G, Shuster LT, Service FJ, Rizza RA, Cobelli C. Incretin effect potentiates β-cell responsivity to glucose as well as to its rate of change: OGTT and matched intravenous study. Am J Physiol Endocrinol Metab 292: E54-E60, 2007.
6. Carson ER, Cobelli C, Finkelstein L. The Mathematical modeling of Endocrine-Metabolic Systems. Model Formulation, Identification and Validation. New York: Wiley, 1983.
7. Cobelli C, Foster D, Toffolo G. Tracer Kinetics in Biomedical Research: from Data to Model. Kluwer Academic/Plenum, New York, 2000.
8. Delgado-Aros S, Kim DY, Burton DD, Thomforde GM, Stephens D, Brinkmann BH, Vella A, Camilleri M. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol 282: G424-G431, 2002.
9. De Nicolao G, Sparacino G, Cobelli C. Nonparametric input estimation in physiological systems: problems, methods, and case studies. Automatica 33: 851-870, 1997. (Pubitemid 127413702)
10. Drucker DJ. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs 12: 87-100, 2003. (Pubitemid 36104645)
11. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705, 2006.
12. Eaton RP, Allen RC, Schade DS, Erickson KM, Standefer J. Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior. J Clin Endocrinol Metab 51: 520-528, 1980.
13. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144: 5149-5158, 2003.
14. Fujimoto W, Miki T, Ogura T, Zhang M, Seino Y, Satin LS, Nakaya H, Seino S. Niflumic acid-sensitive ion channels play an important role in the induction of glucose-stimulated insulin secretion by cyclic AMP in mice. Diabetologia 52: 863-872, 2009.
15. Højberg PV, Zander M, Vilsbøll T, Knop FK, Krarup T, Vølund A, Holst JJ, Madsbad S. Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes. Diabetologia 51: 632-640, 2008.
16. Holst JJ, Bersani M, Johnsen AH, Kofod H, Hartmann B, Orskov C. Proglucagon processing in porcine and human pancreas. J Biol Chem 269: 18827-18833, 1994. (Pubitemid 24226193)
17. Holst JJ, Toft-Nielsen MB, Orskov C, Nauck M, Willms B. On the effects of glucagon-like peptide-1 on blood glucose regulation in normal and diabetic subjects. Ann NY Acad Sci 805: 729-736, 1996. (Pubitemid 27058086)
18. Kwan EP, Gao X, Leung YM, Gaisano HY. Activation of exchange protein directly activated by cyclic adenosine monophosphate and protein kinase A regulate common and distinct steps in promoting plasma membrane exocytic and granule-to-granule fusions in rat islet beta cells. Pancreas 35: e45-e54, 2007.
19. Lindgren O, Mari A, Deacon CF, Carr RD, Winzell MS, Vikman J, Ahrén B. Differential islet and incretin hormone responses in morning versus afternoon after standardized meal in healthy men. J Clin Endocrinol Metab 94: 2887-2892, 2009.
20. Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E. Meal and oral glucose tests for assessment of β-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab 283: E1159-E1166, 2002.
21. Nauck MA, Meier JJ. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 128: 135-148, 2005.
22. Pillonetto G, Sparacino G, Cobelli C. Reconstructing insulin secretion rate after a glucose stimulus by an improved stochastic deconvolution method. IEEE Trans Biomed Eng 48: 1352-1354, 2001.
23. Polonsky KS, Rubenstein AH. C-peptide as a measure of the secretion and hepatic extraction of insulin: Pitfalls and limitations. Diabetes 33: 486-494, 1984.
24. Polonsky KS, Licinio-Paixao J, Given BD, Pugh W, Rue P, Galloway J, Karrison T, Frank B. Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest 51: 98-105, 1986.
25. Schafer SA, Tschritter O, Machicao F, Thamer C, Stefan N, Gallwitz B, Holst JJ, Dekker JM, t Hart LM, Nijpels G, van Haeften TW, Haring HU, Fritsche A. Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 50: 2443-2450, 2007.
26. Schirra J, Wank U, Arnold R, Goke B, Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans. Gut 50: 341-348, 2002.
27. Sparacino G, Cobelli C. A stochastic deconvolution method to reconstruct insulin secretion rate after a glucose stimulus. IEEE Trans Biomed Eng 43: 512-529, 1996.
28. Toffolo G, Breda Cavaghan MK E, Ehrmann DA, Polonsky KS, Cobelli C. Quantitative indexes of β-cell function during graded up-and-down glucose infusion from C-peptide minimal models. Am J Physiol Endocrinol Metab 280: E2-E10, 2001.
29. Toffolo G, Campioni M, Basu R, Rizza RA, Cobelli C. A minimal model of insulin secretion and kinetics to assess hepatic insulin extraction. Am J Physiol Endocrinol Metab 290: E169-E176, 2006.
30. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41: 368-377, 1992.
31. Vella A, Camilleri M. Pharmacogenetics: potential role in the treatment of diabetes and obesity. Expert Opin Pharmacother 9: 1109-1119, 2008.
32. Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes 49: 611-617, 2000.
33. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359: 824-830, 2002.